Your browser doesn't support javascript.
loading
A research center's experience of T-cell-redirecting therapies in triple-class refractory multiple myeloma.
Puertas, Borja; Fernández-Sánchez, Adolfo; Alejo, Elena; Rey-Búa, Beatriz; Martín-López, Ana A; Pérez-López, Estefanía; López-Parra, Miriam; López-Corral, Lucía; Gutiérrez-Gutiérrez, Norma C; García-Sanz, Ramón; Puig, Noemi; González-Calle, Verónica; Mateos, María-Victoria.
Afiliación
  • Puertas B; Hematology Department, University Hospital of Salamanca/ Instituto de Investigación Biomédica de Salamanca/Cancer Research Center IBMCC, Centro de Investigación Biomédica en Red del Cáncer, Salamanca, Spain.
  • Fernández-Sánchez A; Hematology Department, University Hospital of Salamanca/ Instituto de Investigación Biomédica de Salamanca/Cancer Research Center IBMCC, Centro de Investigación Biomédica en Red del Cáncer, Salamanca, Spain.
  • Alejo E; Hematology Department, University Hospital of Salamanca/ Instituto de Investigación Biomédica de Salamanca/Cancer Research Center IBMCC, Centro de Investigación Biomédica en Red del Cáncer, Salamanca, Spain.
  • Rey-Búa B; Hematology Department, University Hospital of Salamanca/ Instituto de Investigación Biomédica de Salamanca/Cancer Research Center IBMCC, Centro de Investigación Biomédica en Red del Cáncer, Salamanca, Spain.
  • Martín-López AA; Hematology Department, University Hospital of Salamanca/ Instituto de Investigación Biomédica de Salamanca/Cancer Research Center IBMCC, Centro de Investigación Biomédica en Red del Cáncer, Salamanca, Spain.
  • Pérez-López E; Hematology Department, University Hospital of Salamanca/ Instituto de Investigación Biomédica de Salamanca/Cancer Research Center IBMCC, Centro de Investigación Biomédica en Red del Cáncer, Salamanca, Spain.
  • López-Parra M; Hematology Department, University Hospital of Salamanca/ Instituto de Investigación Biomédica de Salamanca/Cancer Research Center IBMCC, Centro de Investigación Biomédica en Red del Cáncer, Salamanca, Spain.
  • López-Corral L; Hematology Department, University Hospital of Salamanca/ Instituto de Investigación Biomédica de Salamanca/Cancer Research Center IBMCC, Centro de Investigación Biomédica en Red del Cáncer, Salamanca, Spain.
  • Gutiérrez-Gutiérrez NC; Hematology Department, University Hospital of Salamanca/ Instituto de Investigación Biomédica de Salamanca/Cancer Research Center IBMCC, Centro de Investigación Biomédica en Red del Cáncer, Salamanca, Spain.
  • García-Sanz R; Hematology Department, University Hospital of Salamanca/ Instituto de Investigación Biomédica de Salamanca/Cancer Research Center IBMCC, Centro de Investigación Biomédica en Red del Cáncer, Salamanca, Spain.
  • Puig N; Hematology Department, University Hospital of Salamanca/ Instituto de Investigación Biomédica de Salamanca/Cancer Research Center IBMCC, Centro de Investigación Biomédica en Red del Cáncer, Salamanca, Spain.
  • González-Calle V; Hematology Department, University Hospital of Salamanca/ Instituto de Investigación Biomédica de Salamanca/Cancer Research Center IBMCC, Centro de Investigación Biomédica en Red del Cáncer, Salamanca, Spain.
  • Mateos MV; Hematology Department, University Hospital of Salamanca/ Instituto de Investigación Biomédica de Salamanca/Cancer Research Center IBMCC, Centro de Investigación Biomédica en Red del Cáncer, Salamanca, Spain.
Blood Adv ; 8(13): 3478-3487, 2024 Jul 09.
Article en En | MEDLINE | ID: mdl-38717869
ABSTRACT
ABSTRACT The efficacies of chimeric antigen receptor T cells (CAR-Ts) and bispecific monoclonal antibodies (BiAbs) for triple-class refractory (TCR) myeloma have not previously been compared, and clinical data on how to rescue patients after relapse from these immunotherapies are limited. A retrospective study of 73 TCR patients included in trials was conducted 36 received CAR-Ts and 37 received BiAbs. CAR-Ts produced a higher overall response rate (ORR) than BiAbs (97.1% vs 56.8%, P = .002). After a median of follow-up of 18.7 months, no significant difference in progression-free survival (PFS) was observed between the CAR-T and BiAbs groups (16.6 vs 10.8 months; P = .090), whereas overall survival (OS) was significantly longer in the CAR-T than in the BiAbs group (49.2 vs 22.6 months; P = .021). BiAbs after CAR-Ts yielded a higher ORR and longer PFS2 than did nonredirecting T-cell therapies after CAR-Ts (ORR 87.5% vs 50.0%; PFS2 22.9 vs 12.4 months). By contrast, BiAbs after BiAbs resulted in an ORR of 33% and PFS2 of 8.4 months, which was similar to that produced by the nonredirecting T-cell therapies (ORR 28.6%; PFS2 8.1 months). Although this is a pooled analysis of different trials with different products and the patient profile is different for CAR-Ts and BiAbs, both were effective therapies for TCR myeloma. However, in our experience, although the PFS was similar with the 2 approaches, CAR-T therapy resulted in better OS, mainly because of the efficacy of BiAbs as rescue therapy. Our results highlight the importance of treatment sequence in real-word experience.
Asunto(s)

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Inmunoterapia Adoptiva / Receptores Quiméricos de Antígenos / Mieloma Múltiple Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Blood Adv Año: 2024 Tipo del documento: Article País de afiliación: España

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Inmunoterapia Adoptiva / Receptores Quiméricos de Antígenos / Mieloma Múltiple Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Blood Adv Año: 2024 Tipo del documento: Article País de afiliación: España